United Therapeutics (UTHR) Net Cash Flow (2009 - 2026)

United Therapeutics has disclosed Net Cash Flow across 18 years of filings, most recently posting -$277.4 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$277.4 million, down 236.85% year-over-year; the trailing twelve-month figure through Mar 2026 was -$620.2 million (down 195.65% YoY), and the FY2025 annual result was -$140.1 million, down 128.62% from the prior year.
• Net Cash Flow came in at -$277.4 million for Q1 2026 at United Therapeutics, down from $217.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $217.0 million in Q4 2025 to a low of -$306.8 million in Q2 2025.
• The 5-year median for Net Cash Flow is $43.8 million (2024), against an average of $22.6 million.
• Peak annual rise in Net Cash Flow reached 1885.71% in 2023, while the deepest fall reached 431.49% in 2023.
• United Therapeutics' Net Cash Flow stood at -$5.6 million in 2022, then soared by 1885.71% to $100.0 million in 2023, then soared by 43.3% to $143.3 million in 2024, then surged by 51.43% to $217.0 million in 2025, then sank by 227.83% to -$277.4 million in 2026.
• The last three Net Cash Flow figures came in at -$277.4 million (Q1 2026), $217.0 million (Q4 2025), and -$253.0 million (Q3 2025), per Business Quant data.